# CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma

> **NCT03298828** · PHASE1 · UNKNOWN · sponsor: **Third Military Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Burkitt Lymphoma

## Interventions

- **BIOLOGICAL:** CD19 CAR and PD-1 knock out engineered T-cells
- **BIOLOGICAL:** CD19 CAR T-cells

## Key facts

- **NCT ID:** NCT03298828
- **Lead sponsor:** Third Military Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-11
- **Primary completion:** 2020-10
- **Final completion:** 2022-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2017-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03298828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03298828, "CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03298828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*